110 related articles for article (PubMed ID: 36775996)
1. Estrone analogs as potential inhibitors targeting EGFR-MAPK pathway in non-small-cell lung cancer.
Acheampong F; Ostlund T; Mahnashi M; Halaweish F
Chem Biol Drug Des; 2023 Jun; 101(6):1356-1366. PubMed ID: 36775996
[TBL] [Abstract][Full Text] [Related]
2. Aldolase A promotes proliferation and G
Fu H; Gao H; Qi X; Zhao L; Wu D; Bai Y; Li H; Liu X; Hu J; Shao S
Cancer Commun (Lond); 2018 May; 38(1):18. PubMed ID: 29764507
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.
Qu GP; Shi M; Wang D; Wu JH; Wang P; Gong ML; Zhang ZJ
BMC Pulm Med; 2021 Jul; 21(1):208. PubMed ID: 34210314
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
Jiang Y; Li C; Ma Y; Chen J; Li Y; Chen L
Clin Lab; 2012; 58(5-6):551-61. PubMed ID: 22783588
[TBL] [Abstract][Full Text] [Related]
5. Induction of G2/M Cell Cycle Arrest via p38/p21
Pai JT; Hsu MW; Leu YL; Chang KT; Weng MS
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500594
[TBL] [Abstract][Full Text] [Related]
6. Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways.
Pal HC; Sharma S; Strickland LR; Agarwal J; Athar M; Elmets CA; Afaq F
PLoS One; 2013; 8(10):e77270. PubMed ID: 24124611
[TBL] [Abstract][Full Text] [Related]
7. Altersolanol B, a fungal tetrahydroanthraquinone, inhibits the proliferation of estrogen receptor-expressing (ER+) human breast adenocarcinoma by modulating PI3K/AKT, p38/ERK MAPK and associated signaling pathways.
Siraj MA; Jacobs AT; Tan GT
Chem Biol Interact; 2022 May; 359():109916. PubMed ID: 35346647
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.
Mu X; Zhang Y; Qu X; Hou K; Kang J; Hu X; Liu Y
Biomed Res Int; 2013; 2013():726375. PubMed ID: 23586056
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferation and apoptosis studies of estrone pharmacophores in triple-negative breast cancer.
Acheampong F; Ostlund T; Mahnashi M; Halaweish F
Chem Biol Drug Des; 2023 Nov; 102(5):1050-1066. PubMed ID: 37500540
[TBL] [Abstract][Full Text] [Related]
10. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
[TBL] [Abstract][Full Text] [Related]
11. 20(
Liang Y; Zhang T; Jing S; Zuo P; Li T; Wang Y; Xing S; Zhang J; Wei Z
Am J Chin Med; 2021; 49(3):753-765. PubMed ID: 33641655
[TBL] [Abstract][Full Text] [Related]
12. Sirtuin 7 promotes non‑small cell lung cancer progression by facilitating G1/S phase and epithelial‑mesenchymal transition and activating AKT and ERK1/2 signaling.
Zhao Y; Ye X; Chen R; Gao Q; Zhao D; Ling C; Qian Y; Xu C; Tao M; Xie Y
Oncol Rep; 2020 Sep; 44(3):959-972. PubMed ID: 32705247
[TBL] [Abstract][Full Text] [Related]
13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
14. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
16. α-Lipoic acid inhibits human lung cancer cell proliferation through Grb2-mediated EGFR downregulation.
Yang L; Wen Y; Lv G; Lin Y; Tang J; Lu J; Zhang M; Liu W; Sun X
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):325-331. PubMed ID: 28993193
[TBL] [Abstract][Full Text] [Related]
17. Leveraging Bulk and Single-Cell RNA Sequencing Data of NSCLC Tumor Microenvironment and Therapeutic Potential of NLOC-15A, A Novel Multi-Target Small Molecule.
Lawal B; Wu ATH; Huang HS
Front Immunol; 2022; 13():872470. PubMed ID: 35655775
[TBL] [Abstract][Full Text] [Related]
18. Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer.
Yu SY; Liao CH; Chien MH; Tsai TY; Lin JK; Weng MS
J Agric Food Chem; 2014 Mar; 62(9):2085-95. PubMed ID: 24533688
[TBL] [Abstract][Full Text] [Related]
19. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
20. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A
BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
